Biodexa Pharmaceuticals PLC ADR
BDRX
Biodexa Pharmaceuticals PLC ADR represents shares in a clinical-stage biopharmaceutical company incorporated in England and Wales and headquartered in Cardiff, United Kingdom. The company develops a pipeline of innovative treatments targeting diseases with high unmet medical needs, including familial adenomatous polyposis (FAP), type 1 diabetes, TKI-resistant gastrointestinal stromal tumors (GIST), and primary and metastatic brain cancers. Its lead program, eRapa, is a proprietary oral tablet formulation of rapamycin using nanotechnology and pH-sensitive polymers to enhance bioavailability and consistent pharmacokinetics for FAP, where it is advancing toward a phase 3 registration study known as the Serenta trial. MTX240, licensed from Otsuka, is a next-generation molecular glue for TKI-resistant GIST via selective protein degradation. Tolimidone acts as a selective lyn kinase inhibitor for glycemic control in type 1 diabetes through insulin sensitization. MTX110 delivers panobinostat directly to brain tumors via convection-enhanced delivery, bypassing the blood-brain barrier. Biodexa leverages expertise in formulation science and drug delivery platforms to advance therapies for rare and serious conditions.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£6M
▼ -11.4% YoY
Op. Margin
–
ROIC
-66.58%
▲ +35.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£6M
▲ +51.8% YoY
Op. Cash Flow (TTM)
-£3M
▲ +70.6% YoY
Net Debt
-£8M
Net Cash Position
Cash & Equiv.
£9M
Continue Research
Peers
Biotechnology · Pick stocks to compare with BDRX
Biodexa Pharmaceuticals PLC ADR (BDRX) in three numbers
Questions about Biodexa Pharmaceuticals PLC ADR
Is Biodexa Pharmaceuticals PLC ADR a high-quality business?
Biodexa Pharmaceuticals PLC ADR scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$8M, and its weakest is return on capital at -66.6%. The Quality tab shows every check against its target.
Does Biodexa Pharmaceuticals PLC ADR (BDRX) pay a dividend?
No. Biodexa Pharmaceuticals PLC ADR (BDRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BDRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.